Core Insights - Bausch Health reported a consolidated adjusted EBITDA of $1.05 billion for Q4 2025, a 13% increase, and $3.54 billion for the full year, a 7% increase [1][2] - The company achieved consolidated revenues of $10.27 billion for the full year 2025, up 7% on a reported basis and 5% on an organic basis [1][2] - The fourth quarter revenues reached $2.80 billion, reflecting a 9% increase on a reported basis and a 6% increase on an organic basis compared to Q4 2024 [1][2] Financial Performance - The consolidated net loss attributable to Bausch Health for Q4 2025 was $112 million, compared to a net income of $93 million in Q4 2024 [2] - For the full year 2025, the company reported a net income of $157 million, a significant improvement from a net loss of $46 million in 2024 [2] - Consolidated operating income for Q4 2025 was $474 million, down from $558 million in Q4 2024, primarily due to a goodwill impairment charge of $145 million [2] Segment Performance - The Salix segment reported revenues of $693 million for Q4 2025, a 9% increase, and $2.58 billion for the full year, an 11% increase [1][2] - The International segment generated $306 million in Q4 2025, a 10% increase, and $1.13 billion for the full year, a 2% increase [1][2] - The Bausch + Lomb segment reported revenues of $1.41 billion for Q4 2025, a 10% increase, and $5.10 billion for the full year, a 6% increase [2] Cash Flow and Debt Management - The company generated $495 million in cash from operating activities in Q4 2025, down from $601 million in Q4 2024 [2] - Total cash provided by operating activities for the full year was $1.40 billion, compared to $1.60 billion in 2024 [2] - Bausch Health executed a $1.7 billion debt exchange offer in Q4 2025, extending debt maturities to 2032 [1][2] Strategic Developments - The acquisition of Shibo's full-service aesthetics distribution business in China was completed on December 1, 2025, enhancing the company's market presence [1] - The company continues to focus on strengthening its balance sheet and enhancing shareholder value [2] - Bausch Health is committed to operational excellence and expanding its portfolio as it moves into 2026 [1][2]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's defendants provided misleading information regarding the expected results of its Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that while setrusumab increased bone density, it did not correlate with a decrease in annualized fracture rates, contrary to the positive statements made by the defendants [6].

IGC Pharma (NYSEAM:IGC) Update Summary Company Overview - **Company**: IGC Pharma - **Industry**: Biotechnology, specifically focused on Alzheimer's disease and cannabinoid-based therapies - **Key Personnel**: Ram Mukunda (Chairman and CEO), Ed Woo (Senior Research Analyst at Ascendiant Capital Markets) Core Points and Arguments 1. **Clinical Stage Focus**: IGC Pharma is a clinical stage biotechnology company with a focus on Alzheimer's disease and metabolic disorders, leveraging AI in its research and development efforts [5][7] 2. **Lead Asset**: The lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase II clinical trial (CALMA) targeting agitation associated with Alzheimer's dementia, which affects approximately 50 million people globally [7][35] 3. **Trial Progress**: The CALMA trial is 70% enrolled, with expectations to complete enrollment by mid-2026. The trial aims to address agitation, a symptom present in 76% of Alzheimer's patients [25][26][28] 4. **AI Integration**: IGC Pharma is developing an AI platform (MINT-AD) to stratify risk for Alzheimer's without expensive PET scans, aiming for beta testing in the U.S. within months [11][18][20] 5. **Market Opportunity**: The Alzheimer's market is substantial, with 50 million affected globally. A successful drug for agitation could generate significant revenue, with just 1% market capture equating to $1 billion [35][36] 6. **Differentiation**: IGC-AD1 is expected to act faster than existing treatments, with potential effects observable within 2-3 days, and may also address sleep disturbances in Alzheimer's patients [36][37] 7. **Regulatory Environment**: Recent regulatory changes favor IGC Pharma, including the Mitch McConnell 2026 hemp definition amendment, which could enhance the company's market position and protect its intellectual property [48][49] 8. **Future Trials**: Plans for future trials include investigating the drug's potential for disease modification and cognition improvement, pending completion of a toxicology study [45][46] Additional Important Content 1. **Patient Education**: The company is actively educating potential trial participants about agitation symptoms to improve enrollment, utilizing social media for outreach [29][30] 2. **Global Reach**: IGC Pharma has established connections in various countries, including India and Colombia, to facilitate trials and expand its market presence [22] 3. **Potential Partnerships**: Post-Phase II, the company may seek partnerships or exits, with potential valuations ranging from $750 million to $4 billion depending on interest [41][42] 4. **Broader Applications**: Beyond Alzheimer's, the cannabinoid-based formulation may have applications in other conditions, including pain management and stuttering, with a significant market potential [50][51] This summary encapsulates the key insights from the IGC Pharma update, highlighting the company's strategic focus, market potential, and innovative approaches in addressing Alzheimer's disease and related conditions.

Core Insights - Cosmos Health Inc. is expanding its retail presence in the UK by making its antimicrobial skin cleanser, C-Scrub, available through Superdrug, the second-largest beauty and health retailer in the UK [1][4]. Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group established in 2009, with a portfolio of proprietary pharmaceutical and nutraceutical brands [5]. - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices under European Good Manufacturing Practices (GMP) and is certified by the European Medicines Agency (EMA) [5]. - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, through subsidiaries in Greece and the UK [5]. Product Details - C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infection, thereby supporting effective skin hygiene [4]. - The product's availability in Superdrug's extensive retail and pharmacy network enhances Cosmos Health's market positioning in the UK [4]. Strategic Importance - The entry into Superdrug reinforces the retail momentum for C-Scrub in the UK and strengthens the company's market positioning across various retail platforms [5]. - This expansion is expected to increase brand reach and support the long-term development of Cosmos Health's broader product portfolio in the region [5].

Core Insights - Cosmos Health Inc. is expanding its retail presence in the UK by making its antimicrobial skin cleanser, C-Scrub, available through Superdrug, the second-largest beauty and health retailer in the UK [1][4]. Group 1: Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [5]. - The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including C-Scrub, and operates under European Good Manufacturing Practices (GMP) [5]. - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK, and has established R&D partnerships targeting major health disorders [5]. Group 2: Product Details - C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infection, supporting effective skin hygiene [4]. - The product's availability in Superdrug's extensive retail and pharmacy network enhances Cosmos Health's market positioning in the UK [4]. Group 3: Strategic Importance - The entry into Superdrug reinforces the retail momentum for C-Scrub in the UK, significantly strengthening the company's market positioning across various retail platforms [5]. - This expansion increases brand reach and supports the long-term development of Cosmos Health's broader product portfolio in the region [5].

We recently published 17 Stocks Jim Cramer Talked About.  Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer talked about. Pharmaceutical giant Eli Lilly and Company (NYSE:LLY)’s shares are up by 23.5% over the past year and down by more than 1% year-to-date. Freedom Capital discussed the firm in February as it raised the share price target to $1,200 from $1,050 and upgraded the stock to Buy. The coverage came after Eli Lilly and Company (NYSE:LLY) reported its fiscal fourth quarter and ...

Core Insights - Bristol Myers Squibb (BMY) has received FDA acceptance for the new drug application (NDA) of iberdomide, in combination with daratumumab and dexamethasone, for treating relapsed or refractory multiple myeloma (RRMM) [1][7] - The FDA has granted a priority review for the NDA, with a decision expected on August 17, 2026 [1] - Iberdomide is part of a new class of drugs known as cereblon E3 ligase modulators (CELMoDs), which are under investigation for RRMM treatment [2][8] BMY's Price Performance - Over the past six months, BMY shares have increased by 24.8%, outperforming the industry average rise of 21.4% [3] Iberdomide Development - The NDA filing is based on data from the phase III EXCALIBER-RRMM study, which showed a statistically significant improvement in minimal residual disease (MRD) negativity rates compared to the control arm [4][7] - The study is ongoing, with patients being assessed for progression-free survival [5] Regulatory Designations - Iberdomide has received Breakthrough Therapy designation from the FDA for the treatment of RRMM [2][7] - The review process is part of the FDA's Project Orbis initiative, allowing simultaneous evaluation by regulatory authorities in other countries [8] Strategic Focus - The successful development of iberdomide and other key pipeline candidates is crucial for Bristol Myers as it aims to expand and diversify its portfolio amid challenges from generic competition [9]

LOS ANGELES--(BUSINESS WIRE)---- $STOCKS--Law Offices of Frank R. Cruz Encourages Inovio Pharmaceuticals, Inc. (INO) Shareholders To Inquire About Securities Fraud Class Action. ...

Core Insights - Stocks increased on Wednesday, primarily driven by Big Tech, with Nvidia shares rising 2% following a multiyear partnership with Meta for data center chip usage [1] - WTI crude oil prices rose by 3.4% due to concerns over potential U.S.-Iran hostilities, impacting costs across various sectors [1] - Financial stocks rebounded after a previous decline, with a shift in perception regarding AI's role in enhancing productivity rather than replacing jobs [1] Company-Specific Summaries - Palo Alto Networks experienced a 7.3% decline despite exceeding quarterly expectations, as concerns about AI impacting market share persist; however, the CEO believes AI will ultimately benefit the company [1] - Bristol Myers' stock increased by 27% over three months, driven by the FDA approval of the heart medication Camzyos, but challenges in the Alzheimer's drug trials have raised concerns about future performance [1] - Jim Cramer is considering replacing Bristol Myers with Johnson & Johnson or another high-quality stock due to uncertainties surrounding the company's drug trials [1] Additional Stocks Mentioned - Stocks discussed in the rapid-fire segment included Western Digital, Palantir, Cadence Design Systems, and Analog Devices [1]

Quick Read SPDR S&P Pharmaceuticals ETF (XPH) returned 29.44% over one year versus the S&P 500’s 12%. XPH gained only 10.49% over five years while the broader market returned 74.77%. XPH’s equal weighting amplifies impact of clinical trial failures at smaller portfolio companies. A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here. SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) exists to solve a specific p ...